Organogenesis Holdings (ORGO) Net Cash Flow (2016 - 2026)

Organogenesis Holdings' Net Cash Flow history runs 11 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 91.29% year-over-year to -$2.2 million in Q1 2026; TTM through Mar 2026 was -$18.4 million, a 187.01% decrease from a year earlier, with the FY2025 full-year figure at -$41.8 million, down 231.46% from the prior year.
• Net Cash Flow declined to -$2.2 million in Q1 2026 per ORGO's latest filing, from $30.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $41.2 million in Q4 2024 and bottomed at -$36.8 million in Q2 2025.
• The 5-year median for Net Cash Flow is -$2.2 million (2026), against an average of -$1.3 million.
• Across the five-year window, Net Cash Flow soared 1116.13% in 2024 and slumped 3353.67% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$4.7 million in 2022, then surged by 216.53% to $5.5 million in 2023, then jumped by 647.78% to $41.2 million in 2024, then declined by 27.33% to $30.0 million in 2025, then tumbled by 107.45% to -$2.2 million in 2026.
• Per Business Quant, the three latest ORGO Net Cash Flow figures stand at -$2.2 million (Q1 2026), $30.0 million (Q4 2025), and -$9.4 million (Q3 2025).